References
1. Upson K MS. Epidemiology of Adenomyosis. Semin Reprod Med.
2020;38(2-03):89-107.
2. Puente JM FA, Patel J, Patel A, Cerrillo M, Requena A, Garcia-Velasco
JA. Adenomyosis in infertile women: prevalence and the role of 3D
ultrasound as a marker of severity of the disease. Reprod Biol
Endocrinol. 2016;2016 ; 20;14(1):60.
3. Younes G TT. Effects of adenomyosis on in vitro fertilization
treatment outcomes: a meta-analysis. Fertil Steril.
2017;108(3):483-490.e3.
4. Vercellini P CD, Dridi D, Bracco B, Frattaruolo MP, Somigliana E. .
Uterine adenomyosis and in vitro fertilization outcome: a systematic
review and meta-analysis. Hum Reprod. 2014;29(5):964-977.
5. Nirgianakis K KD, Schwartz ASK, et al. Fertility, pregnancy and
neonatal outcomes of patients with adenomyosis: a systematic review and
meta-analysis. Reprod Biomed Online. 2021;42(1):185-206.
6. Wu Y HJ, Zhong G, Lan J, Lin H, Zhang Q. . Long-term GnRH agonist
pretreatment before frozen embryo transfer improves pregnancy outcomes
in women with adenomyosis. Reprod Biomed Online.
2021;S1472-6483(21)00528-9.
7. Hou X XJ, Shan H, Mei J, Sun Y, Yan G, Sun H, Wang J. The effect of
adenomyosis on IVF after long or ultra-long GnRH agonist treatment.
Reprod Biomed Online. 2020;41(5):845-853.
8. Park CW CM, Yang KM, Song IO. . Pregnancy rate in women with
adenomyosis undergoing fresh or frozen embryo transfer cycles following
gonadotropin-releasing hormone agonist treatment. Clin Exp Reprod Med.
2016;43(3):169-173.
9. Lan J WY, Wu Z, Wu Y, Yang R, Liu Y, Lin H, Jiao X, Zhang Q.
Ultra-Long GnRH Agonist Protocol During IVF/ICSI Improves Pregnancy
Outcomes in Women With Adenomyosis: A Retrospective Cohort Study. Front
Endocrinol (Lausanne). 2021;12:609771.
10. Van den Bosch T, Dueholm M, Leone FP, Valentin L, Rasmussen CK,
Votino A, et al. Terms, definitions and measurements to describe
sonographic features of myometrium and uterine masses: a consensus
opinion from the Morphological Uterus Sonographic Assessment (MUSA)
group. Ultrasound in obstetrics & gynecology : the official journal of
the International Society of Ultrasound in Obstetrics and Gynecology.
2015;46(3):284-98.
11. Bazot M DE. Role of transvaginal sonography and magnetic resonance
imaging in the diagnosis of uterine adenomyosis. Fertility and
sterility. 2018;109(3):389-97.
12. Puissant F VRM, Barlow P, Deweze J, Leroy F. . Embryo scoring as a
prognostic tool in IVF treatment. Hum Reprod. 1987;2(8):705-8.
13. Man Y BY, Zhao S, Zhao R, Xu X, Wei D et al. The effect of different
endometrial preparations on women with polycystic ovary syndrome
undergoing initial frozen embryo transfer: A historical cohort analysis.
Acta Obstet Gynecol Scand. 2021;100:1116-23.
14. Andersch B, Milsom I. An epidemiologic study of young women with
dysmenorrhea. American journal of obstetrics and gynecology.
1982;144(6):655-60.
15. Thalluri V TK. Ultrasound diagnosed adenomyosis has a negative
impact on successful implantation following GnRH antagonist IVF
treatment. Hum Reprod Update. 2012;27(12):3487-3492.
16. Kolanska K CJ, Bendifallah S, Selleret L, Antoine JM,
Chabbert-Buffet N, Darai E, d’Argent EM. Pregnancy outcomes after
controlled ovarian hyperstimulation in women with
endometriosis-associated infertility: GnRH-agonist versus
GnRH-antagonist. J Gynecol Obstet Hum Reprod. 2017;46(9):681-686.
17. Sheng Y MC, Yang R, Liu Z, Liu P, Qiao J. Effects of Different
Controlled Ovarian Hyperstimulation for Adenomyosis on the Outcomes of
IVF-ET. Reprod Contracept. 2010;30(6):375–8.
18. Khan KN KM, Hiraki K, Fujishita A, Sekine I, Ishimaru T, Masuzaki H.
. Changes in tissue inflammation, angiogenesis and apoptosis in
endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy.
Hum Reprod. 2010;25(3):642-53.
19. Tremellen K RP. Adenomyosis is a potential cause of recurrent
implantation failure during IVF treatment. Aust N Z J Obstet Gynaecol.
2011;51(3):280-3.